Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 26;70(47):1640-1645.
doi: 10.15585/mmwr.mm7047e1.

Risk for Stillbirth Among Women With and Without COVID-19 at Delivery Hospitalization - United States, March 2020-September 2021

Affiliations

Risk for Stillbirth Among Women With and Without COVID-19 at Delivery Hospitalization - United States, March 2020-September 2021

Carla L DeSisto et al. MMWR Morb Mortal Wkly Rep. .

Abstract

Pregnant women are at increased risk for severe COVID-19-related illness, and COVID-19 is associated with an increased risk for adverse pregnancy outcomes and maternal and neonatal complications (1-3). To date, studies assessing whether COVID-19 during pregnancy is associated with increased risk for stillbirth have yielded mixed results (2-4). Since the B.1.617.2 (Delta) variant of SARS-CoV-2 (the virus that causes COVID-19) became the predominant circulating variant,* there have been anecdotal reports of increasing rates of stillbirths in women with COVID-19. CDC used the Premier Healthcare Database Special COVID-19 Release (PHD-SR), a large hospital-based administrative database,§ to assess whether a maternal COVID-19 diagnosis documented at delivery hospitalization was associated with stillbirth during March 2020-September 2021 as well as before and during the period of Delta variant predominance in the United States (March 2020-June 2021 and July-September 2021, respectively). Among 1,249,634 deliveries during March 2020-September 2021, stillbirths were rare (8,154; 0.65%): 273 (1.26%) occurred among 21,653 deliveries to women with COVID-19 documented at the delivery hospitalization, and 7,881 (0.64%) occurred among 1,227,981 deliveries without COVID-19. The adjusted risk for stillbirth was higher in deliveries with COVID-19 compared with deliveries without COVID-19 during March 2020-September 2021 (adjusted relative risk [aRR] = 1.90; 95% CI = 1.69-2.15), including during the pre-Delta (aRR = 1.47; 95% CI = 1.27-1.71) and Delta periods (aRR = 4.04; 95% CI = 3.28-4.97). COVID-19 documented at delivery was associated with increased risk for stillbirth, with a stronger association during the period of Delta variant predominance. Implementing evidence-based COVID-19 prevention strategies, including vaccination before or during pregnancy, is critical to reducing the impact of COVID-19 on stillbirths.

PubMed Disclaimer

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Figures

FIGURE
FIGURE
Relative risk for stillbirth among women with COVID-19 at delivery hospitalization compared with those without COVID-19 at delivery hospitalization — Premier Healthcare Database Special COVID-19 Release, United States, March 2020–September 2021,†, Abbreviation: RR = relative risk. * Deliveries with discharge dates during March 2020–June 2021 were considered to have occurred during the period preceding SARS-CoV-2 B.1.617.2 (Delta) variant predominance, whereas those with discharge dates during July–September 2021 were considered to have occurred during the period of Delta predominance. Overall: unadjusted RR = 1.96 (95% CI = 1.74–2.21); adjusted RR = 1.90 (95% CI = 1.69–2.15); pre-Delta: unadjusted RR = 1.52 (95% CI = 1.31–1.77); adjusted RR = 1.47 (95% CI = 1.27–1.71); Delta: unadjusted RR = 4.25 (95% CI = 3.46–5.22); adjusted RR = 4.04 (95% CI = 3.28–4.97); p-value for effect modification by period (pre-Delta period versus period of Delta predominance): <0.001. § Models accounted for within-facility and within-woman correlation, and were adjusted for maternal age, race/ethnicity (Hispanic, non-Hispanic Black, non-Hispanic White, and non-Hispanic other), primary payor (Medicaid, private insurance, and other), obesity, smoking, any diabetes, any hypertension, and multiple-gestation pregnancy.

References

    1. Zambrano LD, Ellington S, Strid P, et al.; CDC COVID-19 Response Pregnancy and Infant Linked Outcomes Team. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22–October 3, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1641–7. 10.15585/mmwr.mm6944e3 - DOI - PMC - PubMed
    1. Allotey J, Stallings E, Bonet M, et al.; for PregCOV-19 Living Systematic Review Consortium. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020;370:m3320. 10.1136/bmj.m3320 - DOI - PMC - PubMed
    1. Ko JY, DeSisto CL, Simeone RM, et al. Adverse pregnancy outcomes, maternal complications, and severe illness among US delivery hospitalizations with and without a coronavirus disease 2019 (COVID-19) diagnosis. Clin Infect Dis 2021;73(Suppl 1):S24–31. 10.1093/cid/ciab344 - DOI - PMC - PubMed
    1. Wei SQ, Bilodeau-Bertrand M, Liu S, Auger N. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ 2021;193:E540–8. 10.1503/cmaj.202604 - DOI - PMC - PubMed
    1. Di Girolamo RD, Khalil A, Alameddine S, et al. Placental histopathology after SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2021;3:100468. 10.1016/j.ajogmf.2021.100468 - DOI - PMC - PubMed